This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
Top Stock Reports for Cisco, Medtronic & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems (CSCO), Medtronic (MDT) and Novo Nordisk (NVO).
FDA Resets PAD Guidelines: The Road Ahead for Device Makers
by Urmimala Biswas
On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.
Cardiovascular Systems Set to Present LIBERTY 360 Outcome
by Zacks Equity Research
This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).
CVS Health Banks on Health Care Benefit Prospects Amid Woes
by Zacks Equity Research
CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition is gaining a strong momentum.
ResMed (RMD) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
ResMed (RMD) gains from promising financial results in the fourth quarter of fiscal 2019.
Here's Why You Should Hold Onto Insulet (PODD) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high on Insulet's (PODD) solid prospects.
Medtronic (MDT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $102.40, marking a +1.41% move from the previous day.
Medtronic (MDT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific Rides on New Products Amid Dull Pacer Sales
by Zacks Equity Research
Within MedSurg, Boston Scientific (BSX) is on track for the year-end launch of Exalt-D Single-Use Duodenoscope, which is used in ERCP procedures.
Baxter (BAX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Canopy Growth Set to Acquire Beckley Canopy Therapeutics
by Zacks Equity Research
With the Beckley Canopy Therapeutics acquisition, Canopy Growth's (CGC) research and development endeavors would be expanding worldwide, thereby making the company a global pioneer in cannabinoid research.
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $101.39, moving +0.15% from the previous trading session.
Is Medtronic (MDT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MDT) Outperforming Other Medical Stocks This Year?
Medtronic (MDT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $102.37 in the latest trading session, marking a +0.42% move from the prior day.
4 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Medtronic (MDT) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Medtronic (MDT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medtronic (MDT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $102.55, marking a +0.45% move from the previous day.
ZBH vs. MDT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ZBH vs. MDT: Which Stock Is the Better Value Option?
Will USTR's 25% Tariff Exemption Spell Relief for MedTech?
by Urmimala Biswas
In the wake of the U.S. tariff and Chinese retaliation, the MedTech industry players (with production houses in China) are facing huge bottom line pressure.
US-India Trade Tensions Rise: 3 Stocks in the Line of Fire
by Sreyoshi Mukherjee
As India moves toward self-sufficiency, U.S. MedTech bigwigs fret over possible losses.
Tap AI-Powered Medical Device Stocks as FDA Bolsters SaMD
by Urmimala Biswas
The whole MedTech community finds a reason to cheer over with the FDA's recent proposal for Software as a Medical Device.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $6 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Medtronic Releases Positive Results of LATERAL Clinical Trial
by Zacks Equity Research
Positive outcomes prove to be a major breakthrough for Medtronic (MDT) in the growing field of ventricular assist devices.
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $98.05, marking a -0.05% move from the previous day.